Biomerica (BMRA) AI Stock Analysis

• Market Cap: $7.92M
• Dividend Yield: N/A
• Average Volume (3M): 44.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: 5.05%
• EPS Growth: 26.13%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -0.06
• Shares Outstanding: 2,545,762
• 10 Day Avg. Volume: 29,731
• 30 Day Avg. Volume: 44,008
• PEG Ratio: -1.04
• Price to Book (P/B): 11.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.15
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 0.30
• Enterprise Value/Gross Profit: 8.63
• Enterprise Value/Ebitda: -0.30
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

Biomerica's financial performance is the primary concern, with significant losses and negative cash flow. The technical analysis shows bearish momentum, while the valuation indicates challenges due to a negative P/E ratio and no dividend yield. These factors collectively result in a below-average stock score.

Biomerica Business Overview & Revenue Model

Company Description

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

How the Company Makes Money

Biomerica makes money through the sale of its diagnostic products and services. The company's revenue model is primarily based on manufacturing and distributing diagnostic tests to healthcare providers, clinical laboratories, and consumers. Key revenue streams include sales of their diagnostic test kits for gastrointestinal diseases and food intolerances, among others. Biomerica also engages in partnerships and collaborations with research institutions and other healthcare entities to expand its product offerings and reach new markets, contributing to its earnings. Additionally, the company may receive revenue from licensing agreements and intellectual property related to its proprietary diagnostic technologies.

Biomerica Financial Statement Overview

Summary

Biomerica faces significant financial challenges, particularly in maintaining profitability and positive cash flows. The income statement reveals ongoing losses with negative net income and EBIT. The balance sheet shows some stability with a positive equity position, but liquidity concerns exist. Cash flow remains negative, indicating inefficiencies and reliance on external funding.

Income Statement

The income statement reveals ongoing challenges with negative net income and EBIT, indicating persistent losses. Revenue growth has been minimal, with a modest increase in the latest TTM period. Gross profit margins remain low, reflecting pricing pressures or higher costs. There is a slight improvement in EBITDA margin, but overall profitability remains weak.

Balance Sheet

The balance sheet shows some stability with a positive equity position and a low debt-to-equity ratio. The equity ratio is healthy, suggesting a solid capital structure. However, total assets have been declining, and liquidity could be a concern given the reduction in cash reserves over time.

Cash Flow

Cash flow remains a significant concern with negative operating and free cash flows, indicating ongoing cash burn. The free cash flow to net income ratio remains unfavorable, highlighting inefficiencies in cash management. While there's been some cash from financing activities, the reliance on external funding is a potential risk.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
5.68M	5.42M	5.34M	18.87M	7.20M	6.69M
	Gross Profit
765.00K	611.00K	446.00K	2.98M	496.98K	1.78M
	EBIT
-5.10M	-6.37M	-7.22M	-4.53M	-6.52M	-2.40M
	EBITDA
-4.69M	-5.99M	-6.74M	-3.94M	-7.06M	-2.27M
	Net Income Common Stockholders
-4.85M	-5.98M	-7.14M	-4.53M	-6.47M	-2.34M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.06M	4.17M	9.72M	5.92M	4.20M	8.64M
	Total Assets
7.38M	9.25M	14.45M	11.37M	11.82M	17.26M
	Total Debt
543.00K	785.00K	1.08M	1.38M	1.62M	1.78M
	Net Debt
-2.52M	-3.38M	-8.64M	-4.54M	-2.58M	-6.86M
	Total Liabilities
1.84M	2.66M	2.73M	3.05M	2.59M	3.05M
	Stockholders Equity
5.53M	6.59M	11.72M	8.32M	9.23M	14.21M
Cash Flow		Free Cash Flow
-4.25M	-5.48M	-5.55M	-650.87K	-5.55M	-4.42M
	Operating Cash Flow
-4.22M	-5.36M	-5.47M	-480.53K	-5.25M	-4.30M
	Investing Cash Flow
-61.00K	-115.00K	-78.00K	-170.34K	-295.58K	-118.93K
	Financing Cash Flow
2.04M	-81.00K	9.39M	2.39M	1.11M	12.37M

Biomerica Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Negative. The current price of 3.11 is below the 20-day moving average (MA) of 3.53, below the 50-day MA of 4.12, and below the 200-day MA of 3.58, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 34.19 is Neutral, neither overbought nor oversold. The STOCH value of 23.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMRA.

Biomerica Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SSKN	54 Neutral	$10.80M	―	-151.23%	―	3.30%	31.84%
Sector *	53 Neutral	$5.14B	3.03	-44.09%	2.83%	16.75%	-0.06%
VVOS	47 Neutral	$13.43M	―	-450.47%	―	9.47%	81.37%
BMRA	45 Neutral	$7.92M	―	-72.70%	―	5.05%	26.13%
NURO	45 Neutral	$9.43M	―	-45.38%	―	-48.61%	32.18%
PAVM	43 Neutral	$11.19M	0.91	-499.57%	―	-33.92%	―
CODX	42 Neutral	$7.81M	―	-56.80%	―	-91.22%	11.84%

Biomerica Corporate Events

Biomerica Announces Reverse Stock Split Effective April 21

On April 16, 2025, Biomerica announced a 1-for-8 reverse stock split effective April 21, 2025, to increase the bid price of its common stock and maintain its Nasdaq listing. This move will reduce the number of outstanding shares from approximately 20.4 million to 2.5 million, while the number of authorized shares remains unchanged. The reverse stock split aims to enhance Biomerica’s market position by ensuring compliance with Nasdaq’s minimum bid price requirements.